Sirnaomics Ltd. (V5Z)

Overview

Sirnaomics Ltd. is an innovative RNA therapeutics biopharmaceutical company, engaged in the discovery and development of unique product candidates to address various medical needs. Since its inception in 2007, the company has been working across the United States, the People's Republic of China, and Hong Kong, focusing on leveraging RNA technology to pioneer treatments for several indications. Its main office is strategically located in Germantown, Maryland, enabling it to tap into a wealth of biopharmaceutical resources and talent.

Products and Services

Sirnaomics Ltd. offers a diverse portfolio of product candidates, each targeting specific medical conditions and aiming to fulfill unmet healthcare needs:

• STP705: Designed for the treatment of cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, liver metastases, keloid scarless healing, hypertrophic scarring, and fat remodeling. This lead candidate exemplifies Sirnaomics' commitment to addressing a wide range of carcinomas and skin-related conditions.
• STP707: Another significant product candidate, it is focused on treating cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, liver fibrosis, and lung fibrosis. STP707 showcases the company’s dedication to combating serious cancers and fibrotic diseases.
• STP355: Currently in development for the broad indication of pan cancer. This illustrates the company's ambition to target a wide range of cancers with a single, innovative approach.
• STP369: Specifically designed to address head and neck/bladder cancer, putting a spotlight on Sirnaomics’ efforts towards tackling less common but equally challenging cancers.
• STP779: Focused on the treatment of liver/lung/pancreatic cancer, demonstrating the biopharmaceutical’s continuous pursuit of solutions for some of the most aggressive and fatal cancers.
• STP702: A unique product candidate for influenza treatment, indicating Sirnaomics Ltd.’s expansion beyond cancer into infectious diseases.
• RIM730: A COVID-19 vaccine, showcasing the company’s responsiveness to global health emergencies and its capability to rapidly pivot its research and development resources to meet immediate and widespread health threats.
• STP122G: Developed for anticoagulation/thrombosis treatment, this candidate broadens the company’s portfolio beyond oncology, offering potential solutions for cardiovascular conditions.
• STP125G: Tailored for treating hypertriglyceridemia, it contributes to the company’s efforts in addressing metabolic disorders.
• STP144G: Embarking on the treatment of complement-mediated diseases, it reflects Sirnaomics' exploration into more niche but highly impactful areas of medicine.